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Objectives. We sought to assess the comparative value of inﬂammatory markers on the occurrence of left ventricular systolic
dysfunction (LVSD) after an acute coronary syndrome (ACS). Methods. During 2006–2008, 760 patients with an ACS were
enrolled. C-reactive protein (CRP) and white blood cell (WBC) count were measured during the ﬁrst 12 hours of hospital
admission. Results. CRP levels and WBC count were signiﬁcantly higher in those who developed LVSD compared to those who did
not. The analysis revealed that a 10mg/dL increase of CRP levels and a 1000/µL increase in WBC are associated with a 6% and a
7% increase in the likelihood of developing LVSD, respectively. Furthermore, WBC count at entry and CRP have almost the same
predictive value for development of LVSD after an ACS (R2 = 0.109 versus R2 = 0.093). Conclusions. Serum CRP levels and WBC
count at entry are almost equally powerful independent predictors of LVSD, after an ACS.
Copyright © 2009 Panagiotis Aggelopoulos et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Heart failure could be described as a modern plague,
as it is the leading cause of hospital admissions in the
United States [1]. Among other diseases leading to heart
failure, coronary heart disease is known to be the main
cause, often implicated by acute heart failure [2]. The
relationship between inﬂammation and heart failure has
been demonstrated in several studies. Among other inﬂam-
matory markers, leukocyte count for men and women
hospitalized for any type of acute coronary syndrome has
been recognized as an independent predictor of hospital
death and development of heart failure [3]. Furthermore,
inﬂammatory markers such as CRP, IL-6, and TNFa, are
associated with increased risk of congestive heart fail-
ure in older people without prior myocardial infarction
[4, 5]; while CRP is strongly and independently associ-
ated with the occurrence of new onset heart failure [6–
11].
The assessment of the risk for developing left ventricular
systolic dysfunction and eventually systolic heart failure in
ACS patients is of considerable clinical and public health
importance; while the comparative role of CRP and WBC
count in occurence of left ventricular systolic dysfunction in
the setting of ACS is still unclear.
The aim of this study is to investigate the implication
of inﬂammation, characteristically expressed by the levels
of CRP, and white blood cell count, on the occurrence
of LVSD in the acute coronary syndrome (ACS) process,
thus providing insights in the contribution of inﬂam-
mation to the deterioration of the systolic function of
the heart in the setting of ACS. Moreover, we aim to
estimate the comparative predictive value of the two markers
assessed.2 Mediators of Inﬂammation
2. Methods
2.1. Population of the Study. During 2006–2008, we enrolled
798 consecutive patients who developed an ACS event. From
the above we ﬁnally included in the study 283 males (64±14
years) and 73 females (71 ± 12 years) postacute coronary
syndrome patients with impaired ejection fraction, deﬁned
as below 40% and 317 males (62 ± 11 years) and 87 females
(67 ± 11 years) with normal ejection fraction, deﬁned as
above 50%. The total number of patients were therefore
760, while the rest 38 exhibited an ejection fraction of
40–50% and were not included in the following analysis.
Patients that were estimated as having an EF of 40–50%
were not included, as this is only mild impairment of
ventricular function. The echocardiographic evaluation of
the left ventricular function that was used in this analysis was
the one performed at the discharge day, in order to overcome
the stunning of the ﬁrst days after the acute coronary
event.
2.2. Diagnosis of ACS. At entry a 12-lead electrocardiogram
was performed, and clinical symptoms were evaluated in
all patients, by a cardiologist of the study. Based on the
electrocardiographic ﬁndings patients were classiﬁed as
having ST-segment elevations, non-ST segment elevations,
or other electrocardiographic abnormalities. Moreover, tro-
ponin I measurements were performed to detect evidence of
myocardial cell death. We included only cases with diagnosis
of ACS (acute myocardial infarction (MI) or unstable
angina (UA)). In particular, acute myocardial infarction
was deﬁned according to the latest guidelines [12]; while
unstable angina was deﬁned by the occurrence of one or
more angina episodes, at rest, within the preceding 48 hours,
corresponding to class III of the Braunwald classiﬁcation
[13].
Using a Hewlett Packard 5500 Sonos with a multifre-
quency transducer (2, 5-4MHz) we evaluated the systolic
function of the left ventricle during the ﬁrst 48 hours and
at the discharge day. Systolic heart failure was deﬁned as
left ventricular ejection fraction at the discharge day below
40%, according to the recent European Society of Cardiology
guidelines for the diagnosis and treatment of acute heart
failure [1]. For this reason we excluded from this study those
patients with an ejection fraction of the left ventricle above
40% and below the normal limits of 50%, as those represent
mild impairment of left ventricular function at the discharge
day.
The study was approved by the Medical Research Ethics
Committee of our Institution and was carried out in
accordance with the Declaration of Helsinki (1989) of the
World Medical Association, while each patient gave written
consent for participating.
2.3. Other Clinical and Biochemical Characteristics. In all
patients a detailed medical history was recorded, including
previoushospitalizationforcardiovasculardisease(i.e.,coro-
nary heart disease, stroke, or other cardiovascular disease),
presence and management of hypertension, hypercholes-
terolemia, renal failure, and diabetes mellitus. Moreover, we
recorded patients’ medical family history. In addition to
troponin I, we also measured the MB fraction of creatine
phosphokinase (CPK), urea, and uric acid. The biochemical
evaluation was carried out in the same laboratory that
followed the criteria of the World Health Organization
Reference Laboratories. Total-, high-density lipoprotein,
cholesterols, blood glucose, and triglycerides were also
measured in all participants, using colorimetric enzymic
method in a Technicon automatic analyzer RA-1000 (Dade-
Behring Marburg GmbH, Marburg, Germany). Low-density
lipoprotein cholesterol was calculated using the Friede-
wald formula: total cholesterol—HDL cholesterol—1/5 ×
(triglycerides). An internal quality control was in place
for assessing the validity of cholesterol and triglycerides
methods. The intra- and interassay coeﬃcients of varia-
tion of cholesterol and triglycerides levels did not exceed
4%.
White blood cell count was measured at the initial blood
test at entry, and C-reactive protein levels were measured
during the ﬁrst 12 hours of hospitalization, speciﬁcally at
9:00 a.m. of the next morning. CRP levels were measured by
nephelometry.
Renalinsuﬃciencywasinitiallyquantiﬁedbythebaseline
estimated creatinine clearance rate (CrCl). Based on baseline
serum creatinine (Cr), the CrCl was calculated using the
Cockcroft-Gault formula (14): CrCl = [[(140 − age) ×
weight] / (72 × serum creatinine)] for men, while for female
gender, the result of the above equation was multiplied by
0.85 [14].
2.4. Demographic, Anthropometric, and Lifestyle Character-
istics. Sociodemographic characteristics included age, sex,
marital status, number of children, years of school, type
of occupation. Height and weight were measured and to
the nearest 0.5cm and 100g, respectively. Body mass index
(BMI) was then calculated as weight (in kilograms) divided
by height (in meters) squared. Physical activity was deﬁned
as any type of exercise (occupational or leisure) at least
once per week during the past year. Other participants were
deﬁned as physically inactive. Current smokers were deﬁned
as those who smoked at least one cigarette per day or
have stopped cigarette smoking during the past 12 months.
Former smokers were deﬁned as those who had stopped
smoking more than one year previously. The rest of them
were deﬁned as never smokers or rare smokers.
2.5. Statistical Analysis. In this work continuous variables
are presented as mean values ± standard deviation. The
categorical variables are presented as absolute and relative
(%) frequencies. Associations between continuous variables
andgroups ofpatients wereevaluatedthroughtheanalysisof
variance(ANOVA),aftercontrollingforequalityofvariances
(homoscedacity). Associations between categorical variables
were tested by the use of the chi-squared test, without the
correction of continuity. Correlations between continuous
variables were tested by the use of Pearson’s correlation
coeﬃcient. Due to multiple comparisons we applied the
Bonferroni correction to correct for the inﬂation of Type—I
error. Logistic regression analysis was applied in order toMediators of Inﬂammation 3
Table 1: Clinical characteristics of the patients according to systolic heart function.
With LVSD Without LVSD P
N 356 404
Age (yrs) 66 ±14 63 ±12 .17
Male sex (%) 80 78 .58
BMI (Kg/m2)2 7 .5 ±42 8 ±5. 1 4
Systolic blood pressure at entry 128.6 ±29.2 133.6 ±26 .013
Diastolic blood pressure at entry 75.5 ±14 77.4 ±13 .05
Heart rate at entry 81 ±16 79 ±16 .71
Diagnosis MI (%) 84 71 <.0001
Number of Vessel disease 2 ±0.91 .8 ±0.9 <.0001
Previous CHD (%) 49 47 .62
Time delay (min) 548 ±1953 651 ±2702 .65
Troponin I at entry 40.28 ±72.77 16.74 ±39.43 <.0001
Uric acid (mg/dL) 6.69 ±2.15 6.14 ±2.02 <.0001
Blood glucose at entry (mg/dL) 166 ±89 151 ±82 .01
CRP (mg/L) 43.63 ± 52.97 26.9 ±42 <.0001
WBC count 11123 ±10726 9856 ±5180 .05
Creat clear (mL/min) 72 ±34 78 ±32 .01
Ht (%) 41.4 ±5.44 1 .4 ±5.0. 9 3
LDL (mg/dL) 125.36 ±46.33 127.23 ±44.6. 5 9
Prior statin therapy (% hyperlipidemics) 44 42 .21
Current smoking % 49 47 .49
Physical activity (%) 58 66 .30
Hypertension (%) 59 62 .36
Receiving medication for hypertension (%) 41 49 .32
Diabetes mellitus (%) 36 30 .13
Receiving oral medication for diabetes mellitus (%) 31 36 .08
Insulin therapy (%) 30 33 .18
LVSD indicates left ventricular systolic dysfunction; BMI indicates body mass index; Ht indicates hematocrit; Time delay = time in minutes from symptoms
onset till hospitalization; Previous CHD: previous known coronary heart disease.
evaluate the association between the investigated inﬂamma-
tory markers and the development of LVSD, after various
adjustments were made. Deviance residuals and Hosmer-
Lemeshow criterion were used to test models’ goodness-of-
ﬁt. All statistical calculations were performed on the SPSS
version 12.0 software (SPSS Inc, Texas, Ill, USA.).
3. Results
Table 1 illustrates the clinical characteristics of the patients
according to the presentation or not of LVSD at discharge.
Patients who developed systolic dysfunction had lower sys-
tolic and diastolic blood pressure at entry, higher entry levels
oftroponin I,glucose,uricacid,WBCcountandserumCRP,
lower creatinine clearance as well as higher prevalence of
myocardial infarction as a discharge diagnosis. Furthermore,
they had more extensive coronary artery disease according
to their coronary angiogram, while there was no signiﬁcant
diﬀerence regarding smoking habits, physical activity status,
hypertension, hypercholesterolemia, previous medication
and previous history of CHD, body mass index, age, and sex.
Then, we divided WBC count in tertiles (lower tertile
< 8180/µLa n du p p e rt e r t i l e> 11000/µL) and we revealed
that those patients in the upper tertile were younger, had
more often myocardial infarction than unstable angina, had
higher levels of troponin I at entry, had less often previous
history of coronary heart disease, and were more often
current smokers (Table 2). Similarly, we divided CRP levels
in tertiles (lower tertile < 6.52mg/L and upper tertile >
28mg/L) and we revealed that those patients in the upper
tertile were older, had more often myocardial infarction
rather than unstable angina, had higher levels of troponin
I at entry, and had lower levels of creatinine clearance
(Table 3).
Logistic regression analysis, after controlling for sex, age,
diagnosis of myocardial infarction, troponin I levels at entry,
systolic and diastolic blood pressure levels at entry, and
creatinine clearance, revealed that an increase per 10mg/L
of serum CRP levels independently increases by 6% the
likelihood of developing LVSD after an acute coronary
event (OR = 1.00610, P = .002) (Table 4). Moreover, after
controlling for the same confounders as before, we revealed
that an increase of 1000 count of WBC count at entry is
independently associated with an increase by 7% of the
likelihood of developing LVSD after an acute coronary event
(OR = 1.000071000, P<. 001) (Table 4).4 Mediators of Inﬂammation
Table 2: Results from ANOVA that presents the distribution of clinical and biochemical characteristics among WBC tertile.
1st tertile 2nd tertile 3rd tertile P
WBC < 8180/µL < 8180WBC < 11000/µLW B C > 11000/µL
N 225 235 237
Age (yrs) 67.9 ± 11.86 4 .2 ±12.46 1 .6 ±12.5 <.0001
Male sex % 76 80 82 .287
Body mass index (Kg/m2)2 7 .3 ±4.32 8 .4 ±5.52 7 .8 ±3.9 .132
Time delay (min) 830.8 ±3421 343.5 ±763.3 655.7 ±2178 .251
Presence of MI, % 63 77 90 <.0001
History of CHD, % 45 35 24 <.0001
Troponin I at entry (ng/mL) 5.56 ±22.68 8.90 ±25.46 14.87 ±38.04 .004
Smoking, % 34 54 56 <.0001
Hypertension, % 63 63 58 .480
Diabetes % 35 28 33 .303
Hypercholesterolemia, % 55 60 58 .754
Creatinine clearance 68.33 ±30.57 9 .75 ±33.27 8 .28 ±33.4 <.0001
Systolic blood pressure at entry (mm Hg) 129.5 ±26 131 ±26 133 ±31 .26
Diastolic blood pressure at entry (mm Hg) 76 ± 12 77 ±13 77 ±15 .55
Heart rate at entry (beats/min) 78 ± 15 75 ±13 90 ±16 .05
Time delay: time in minutes from symptoms onset till hospitalization; MI: myocardial infarction; History CHD: previous known coronary heart disease.
Table 3: Results from ANOVA that presents the distribution of clinical and biochemical characteristics among CRP tertile.
1st tertile 2nd tertile 3rd tertile P
CRP < 6.52 mg/L < 6.52CRP < 28mg/L CRP > 28mg/L
N 207 209 204
Age (yrs) 63 ±12.66 3 .2 ±13.46 6 .3 ±12.5 .014
Male sex % 80 77 81 .549
Body mass index (Kg/m2)2 8 .1 ±5.82 7 .7 ±4.32 7 .7 ±4 .709
Time delay (min) 836.7 ±3860 609.5 ±2191 551.7 ±1600 .721
Presence of MI, % 75 85 90 <.0001
History of CHD, % 31 28 26 .625
Troponin I at entry (ng/mL) 6.08 ±25.95 11.72 ±28.05 17.43 ±45.84 .006
Smoking, % 45 53 51 .221
Hypertension, % 63 56 59 .310
Diabetes % 27 30 35 .180
Hypercholesterolemia, % 62 59 51 .299
Creatinine clearance 79.35 ±33.77 7 .02 ±33.56 8 .96 ±31.9 .007
Systolic blood pressure at entry (mm Hg) 131 ±25 131 ±28 133 ±32 .97
Diastolic blood pressure at entry (mm Hg) 77 ±12 76 ±13 76 ±15 .68
Heart rate at entry (beats/min) 73 ±25 80 ±15 85 ±16 .28
Time delay: time in minutes from symptoms onset till hospitalization; MI: myocardial infarction; History CHD: previous known coronary heart disease.
We used two logistic regression models using the same
confounders each time and entering CRP the ﬁrst time and
WBC count afterwards. Comparing the R Square for the
two logistic regression models, that is to say, the amount
of variance explained by each model, we observe that WBC
count seems to be slightly but not signiﬁcant more powerful,
in predicting the development of left ventricular systolic
dysfunction, than CRP (R2 = 0.109 versus R2 = 0.093).
(Table 4).
4. Discussion
In this study we revealed that higher values of white
blood cell count are associated with higher probability
of developing left ventricular systolic dysfunction after an
acute coronary syndrome, independently of diagnosis of
myocardial infarction or other common conditions that
might contribute to this. We also demonstrated that CRP is
an independent predictor of development of left ventricularMediators of Inﬂammation 5
Table 4: Results from logistic regression model that evaluated the
role of CRP and WBC (independent covariates) on the occurrence
of LVSD in patients who had had an acute coronary event, after
adjustment for several common confounders∗.
Odds ratio 95% conﬁdence
interval
Model 1: CRP (per mg/L) 1.06 1.02–1.10
Model 2: WBC (per 1000 count) 1.07 1.02–1.12
∗Covariates also used in both models were age, sex, diagnosis of myocardial
infarction, creatinine and troponin I levels at entry, systolic, and diastolic
blood pressure levels at entry.
systolic dysfunction after an ACS, as well, after controlling
for common confounders (including myocardial infarction
diagnosis). Although WBC count seems to be a slightly
more powerful predictor for the development of systolic
dysfunction than CRP, this diﬀerence was not statistically
signiﬁcant.
In the setting of acute coronary syndromes, inﬂamma-
tion is known to have a key role in disease progression and
development of complications. We assessed left ventricular
dysfunction occurrence using two widely used and easily
measured markers: CRP is a proven marker of inﬂammation,
yet the WBC count seem to hold its role in predicting poor
prognosis in a manner that exceeds just inﬂammation.
4.1. WBC and Acute Systolic Heart Failure. It is well known
that the leucocyte count is elevated in the setting of
myocardial infarction. Leukocytes are the ﬁrst cells drawn to
an infarct area of necrosis trying to repair the tissue damage.
As we revealed in our study that the initial WBC count seems
to be higher in younger patients, who more frequently suﬀer
frommyocardialinfarctionratherthanunstableangina,have
higher heart rate at entry, have higher troponin I levels, have
less frequently prior history of coronary heart disease, and
are more often current smokers (Table 2). These correlations
are more or less expected and form a patient proﬁle that is
previously linked to congestive heart failure occurence after
an ACS [15], while smoking is recently also associated with
WBC count and worse hospital and short-term prognosis in
an analysis from GREECS study [16].
The leukocytes seem to mediate left ventricular systolic
dysfunction in the setting of an acute coronary syndrome
in many ways; elevated white blood cell count is associated
with more extensive coronary artery disease, as assessed
by coronary angiography [17]. Leukocytes are also associ-
ated with worse myocardial perfusion that can be due to
microvascular plugging and abnormal leucocyte aggregation
[18], a mechanism that might contribute to the “no-
reﬂow” phenomenon. In another study of stable angina
patients, neutrophil count was associated with coronary
vascular stenosis complexity [19]. Another mechanism is
that of myocardial infarct expansion that can be partly
mediated through binding of the leucocytes through adhe-
sion molecules to the microvascular endothelium. Moreover,
leucocytes may mediate injury through releasing proteolytic
enzymes and oxidative radicals. In experimental models,
neutropenia was associated with smaller infarct sizes [20].
It appears that leykocytes may have an important role
in tissue repair, but seem to enhance a portion of further
tissue damage, thus explaining their contribution to the
development of systolic dysfunction, regardless of the infarct
itself.
4.2. CRP and Acute Systolic Heart Failure. It is previously
shown that CRP is elevated in cases of myocardial infarction,
as CRP rises in response to various inﬂammatory stimuli,
including tissue necrosis and myocardial infarction [21, 22].
During destabilization of coronary heart disease, cytokines
releasedbyinﬂammatorycellsmediatefurtherinﬂammatory
cell migration and cardiac repair and, particularly IL-6,
mediatesCRPelevation[23].ThesecorrelationsbetwenCRP
and myocardial necrosis were observed in our study as well
(Table 3). Moreover, higher CRP levels were observed in
older patients and in those with lower creatinine clearance.
CRPmaybelinkedtoleftventricularsystolicdysfunction
progression through three diﬀerent mechanisms: its relation
to the extent of coronary artery disease, its relation to
thrombus burden, and the proinﬂammatory eﬀect that
may mediate further tissue damage in cases of myocardial
infarction. CRP is reported to be associated to CAD extent
in myocardial infarction patients [24] but nonetheless in
unstable angina patients the correlation is reported to
be weak [25]. It is best linked to the overall thrombus
burden, as CRP is recognised to have procoagulant eﬀects
through stimulating tissue factor production. Furthermore,
it is reported that CRP mediates further inﬂammatory
stimulation and maybe implicated in augmenting theinfarct
damage through the action of inﬂammatory cells [24].
ItisknownthatCRPconcentrationdemonstratesdiurnal
variation that is statistically signiﬁcant and may bias epi-
demiological studies [26, 27]. CRP levels in STEMI patients
are higher during daytime, in contrast to nighttime. In
our study, however, blood samples for CRP measurement
were drawn at 9:00 a.m. for all patients, in both study
groups, so diurnal variation is not expected to bias our
results. As for seasonal heterogeneity, CRP concentration
demonstrates only a tendency for higher values in the colder
months that is moreover of borderline statistical signiﬁcance
[26]. Furthermore, CRP levels do not present signiﬁcant
ﬂuctuationsattributedtogender,phaseofmenstrualcycle,or
useofaconventionalneedleforthedrawingofbloodsamples
[26]. In our study CRP measurements were performed
within1-2hoursofbloodcollection,sothereisnosigniﬁcant
delay in processing the sample [26].
Among the two inﬂammatory markers assessed in this
work, the WBC count seems to have a slightly better
predictive power for the development of left ventricular
systolic dysfuncton after an ACS, when compared to CRP.
CRP is related to systolic dysfunction after an ACS through
three diﬀerent mechanisms: that of total atherosclerotic
burden which means that it is related to more extensive
coronary vascular disease, that of thrombus burden which
means that having procoagulant eﬀects, may account for a
portion of thrombus formation, and that of inﬂammatory
escalation. On the other hand, leukocytes are implicated
more actively and in more pathophysiologic steps than CRP;6 Mediators of Inﬂammation
they are related to more extensive coronary vascular disease
and they contribute to inﬂammatory escalation, oxidative
stress, proteolytic enzymes release; microvascular plugging,
lytic action of macrophages. This can partly explain the
ﬁndings of another study that associates high neutrophil
count (among all leucocyte subtypes) with higher mortality
rates following an ACS, independently of CRP levels [9]
and is partly explained by the various mechanisms of tissue
damaging, apart from inﬂammation.
4.3. Study Limitations. In retrospective case-control studies,
two main sources of systematic errors may exist, the
selection and the recall bias. In order to eliminate selection
bias we tried to set objective criteria, both for patients
and controls having the same echocardiographic evaluation
of left ventricular function obtained by two independent
physicians at the discharge day, in order to eliminate the
impact of stunning myocardium of the ﬁrst days after the
event. Also, in case-control studies, it is usually observed
that patients who had a recent adverse event are more
likely to place greater emphasis (overestimate) on several
factors related to the disease than the control group (recall
bias). In order to reduce this type of bias, we made an
eﬀort to obtain accurate information from the patients as
well as from their relatives or their accompanying persons.
Besides, the two groups were patients with diﬀerent disease
severity. Another limitation is that we have also included
patients with previous history of coronary heart disease.
These patients may have had impaired left ventricular
function before the index event. In order to eliminate this
bias we have included the information of previous known
history of coronary heart disease in the multivariate analysis;
the percentage of patients with previous CHD history
had no signiﬁcant diﬀerence between the two groups of
patients.
The CRP assay was not a high sensitivity one, but this
fact is not expected to inﬂuence our results, as all patients
are suﬀering from an acute coronary syndrome and are,
therefore, expected to exhibit elevated values of CRP.
Concerning the medical information, we tried to avoid
recall bias by obtaining accurate and detailed data from
subjects’ medical records. However, over/under estimation
may still exist, especially in the measurement of smoking
habits and the onset of the investigated cardiovascular risk
factors. Moreover, the coronary patients who died at entry or
the day after were not included in the study. This bias could
inﬂuence our results, but, since the proportion of deaths
during the ﬁrst two days was estimated between 2–4%, we
believe that the inability to include the fatal events did not
alter signiﬁcantly our ﬁndings. Furthermore, regarding the
potential eﬀect of uncontrolled—unknown confounders, we
tried to reduce it by using the same study base, both for
patients and controls, but their inﬂuence on the outcome
may still exist.
4.4. Conclusions. Elevated WBC and CRP levels are indepen-
dent predictors of development of left ventricular systolic
dysfunction after an ACS, regardless of several confounders
including diagnosis of myocardial infarction. The WBC
count seems to be slightly more predictive than CRP in
this direction. Hopefully clinicians may consider the initial
WBC count and CRP as almost equally powerful measures of
possible left ventricular systolic dysfunction occurence, that
may lead to heart failure. The inﬂammatory process may also
be targeted for therapy, as this may provide some protection
against heart failure occurrence.
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